Canadian CANNAINVESTOR Magazine January 2018 | Page 147

Lexaria Bioscience P E R F O R M • R E C O V E R Lexaria Bioscience Corp. CSE:LXX | OTCQB:LXRP Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company’s lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also masking taste. Cannabinoids are poorly absorbed by the body’s gastrointestinal tract and consumers often default to alternate routes of administration like smoking to achieve higher effectiveness. The Company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. Lexaria’s propiertary technology delivers the following advantages for cannabinoid edibles: 1) Masks taste – eliminates the undesired taste in cannabinoid edibles, enabling zero-sugar formats. 2) Reduces time of onset – effects are felt within 15-20 min vs. 60-120 min. 3) Increases bio-absorption – by 5 – 10X, to equate that of inhalation. Business Model: 1) Out-license (royalty) the technology to third-party partners / distributors. Range: 5-10% of gross sales. Seven deals signed/pending (3 definitive agreements, 4 LOI/MOU’s pending). 2) Product Sales - Lexaria sells hemp oil CBD ( cannabidiol ) products. Lexaria’s branded protein energy bars are excellent for energy, fiber and protein. ViPova™ branded premium teas deliver CBD in several flavors. TurboCBD TM hemp oil capsules are formulated with Ginseng & Ginkgo for enhanced focus and memory. Patent Portfolio - 19 patent applications filed in US, International (under the Patent Cooperation Treaty), and national filings in 44 countries. Patents include both method and composition of matter claims. Patent issued in USA, Australia: “Cannabinoid Infused Food and Beverage Compositions and Methods of Use Thereof”. Additional patent issuances are expected to follow, including THC. Other molecules are also captured within the patent applications and represent future research opportunities. These include: Nicotine, Fat Soluble Vitamins (e.g., A, D, K & E), NSAIDs (non-steroidal anti-inflammatory drugs such as ibuprofen). Collaborative Research Agreement with National Research Council to investigate opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions. Key Executives: Stock Information: Chris Bunka - Chairman & CEO. Trading symbol: CSE:LXX, OTCQB:LXRP Shares o/s: 67m, (f/d: 79m) Mgmt & Insiders: 14m (21%) Recent price: C$0.42 / US$0.35 Serial entrepreneur, extensive experience in the capital markets, corporate governance, M&A and finance. John Docherty, M.Sc. - Director & President. 20 yr. senior executive in the pharmaceutical and bioscience M.Sc. in pharmacology and B.Sc. in toxicology from the University of Toronto. Mr. Ted McKechnie – Director. Senior entrepreneurial executive with extensive senior management & board experience in the consumer goods industry in National and Retail brands. Former President and COO of Maple Leaf Foods. For more information, contact Alex Blanchard, Communications Manager: [phone], Email: [email protected] This Fact Sheet is provided by Lexaria Bioscience Corporation as a convenience for potential investors. More details about the business and its risks can be found in the Company’s press releases and filings with the U.S. Securities and Exchange Commission or the Canadian Securities Administrators. This Fact Sheet contains forward-looking statements and actual results may differ materially from such statements. www.lexariabioscience.com Sept 2017